Results 91 to 100 of about 18,827 (200)

Altering distribution profile of palbociclib by its prodrugs

Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, is currently used clinically for treating hormone receptor-positive and human epidermal growth factor receptor 2 negative breast cancer.
Elmquist, William, Huttunen, Kristiina, Järvinen, Juulia, Leppänen, Jukka, Jalkanen, Aaro J., Laitinen, Tuomo, Adla, Santosh, Rautio, Jarkko, Montaser, Ahmed, Lehtonen, Marko, Vellonen, Kati-Sisko, Timonen, Juri Mikael   +11 more
core   +1 more source

Does CDKN2A Loss Predict Palbociclib Benefit?

, 2015
Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and Drug Administration in combination with letrozole for postmenopausal women with advanced hormone receptor–positive, her2 ...
R.P. Adams, J. Gao, S.M. Swain
core   +1 more source

Early‐Phase Research in Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Jonathan Cunningham
wiley   +1 more source

Advances in FGF/FGFR Signaling: Implications for Disease and Therapy

MedComm, Volume 7, Issue 9, September 2026.
The FGF/FGFR signaling is indispensable for the maintenance of physiological homeostasis and governs multiple biological processes, including embryonic development, bone metabolism, angiogenesis, and neurogenesis, whereas aberrant hyperactivation of this pathway drives the progression of malignancies and autoimmune disorders, including inflammatory ...
Miaoyu Song, Xi Liu, Yang Xiao, Yongsheng Li, Huakan Zhao   +4 more
wiley   +1 more source

Cellular uptake and efflux of palbociclib in vitro in single cell and spheroid models [PDF]

, 2019
Adequate drug distribution through tumours is essential for treatment to be effective. Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor approved for use in patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer ...
Brook, BS, Holden, E.C., Hubbard, Matthew E, Spencer, Jade A, Smye, Stephen W, Loadman, P, Twelves, Christopher J, Spencer, JA, Spencer, Jade A., Loadman, Paul, O'Dea, RD, Hubbard, M.E., Smye, S.W., Brook, B.S., O'Dea, Reuben D, O'Dea, R.D., Jove, M, Holden, Elizabeth C, Jove, Maria, Jove, M., Holden, EC, Brook, Bindi S, Phillips, Roger M., Hubbard, ME, Twelves, C.J., Phillips, RM, Phillips, Roger M, Smye, SW, Twelves, CJ   +28 more
core   +1 more source

Quercetin inhibits the epithelial-mesenchymal transition and reverses CDK4/6 inhibitor resistance in breast cancer by regulating circHIAT1/miR-19a-3p/CADM2 axis.

PLoS ONE
Breast cancer (BC) cells have a high risk of metastasis due to epithelial-mesenchymal transition (EMT). Palbociclib (CDK4/6 inhibitor) is an approved drug for BC treatment.
Xiaogang Li, Chao Niu, Guoqiang Yi, Yuan Zhang, Wendi Jin, Zhiping Zhang, Wanfu Zhang, Bo Li   +7 more
doaj   +1 more source

High‐Content CRISPR Screening: Methods and Applications

MedComm, Volume 7, Issue 9, September 2026.
High‐content CRISPR screening represents a paradigm shift in functional genomics, moving beyond traditional survival‐based readouts to enable multidimensional mapping of genotype–phenotype relationships. This review systematically outlines the methodological evolution of this approach, detailing advances in perturbation modalities, delivery systems ...
Yike Zhang, Yimeng Zhang, Xudong Tang, Xinyu Deng, Yitian Zhou, Yanfeng Wu, Jianhua Luo   +6 more
wiley   +1 more source

Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development

Cancer Science, Volume 117, Issue 9, Page 2335-2344, September 2026.
Dysregulated cell cycle control often involves alternative compensatory pathways in cancers to maintain its robustness but provide unique targetable vulnerabilities. We overview recent insights on cancer‐specific vulnerabilities across the cell cycle and discuss how these can be used to develop new therapeutic strategies.
Nana Kamakura, Minji Jo, Motoko Takahashi, Toru Hirota   +3 more
wiley   +1 more source

Understanding Postmarketing Requirements and Commitments for CYP3A‐Mediated Drug–Drug Interactions: An Analysis of FDA‐Approved Drugs From 2015 to 2024

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Addressing knowledge gaps at drug approval through drug–drug interaction (DDI)‐related postmarketing requirements (PMRs) and commitments (PMCs) is essential for safe and effective use. This analysis reviewed CYP3A‐related PMRs and PMCs, the most evaluated enzyme in postmarketing studies, to characterize their scope.
Jingjing Yu, Ichiko Petrie, Sophie Argon, Katie Owens, Isabelle Ragueneau‐Majlessi   +4 more
wiley   +1 more source

Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy

, 2019
While clinical responses to palbociclib have been promising, metastatic breast cancer remains incurable due to the development of resistance. We generated estrogen receptor-positive (ER+) and ER-negative (ER−) cell line models and determined their ...
Stephanie Vega, Lilibeth Lanceta, Alana Gipson, Rodolfo Garza-Morales, Jason Chesney, Jorge Gomez-Gutierrez, Kelly McMasters, Nadiia Lypova, Yoannis Imbert-Fernandez   +8 more
core   +1 more source